BRIEF-Tarsus Pharmaceuticals Q2 EPS USD -0.43
Reuters2026/08/06 11:04Aug 06 (Reuters) - Tarsus Pharmaceuticals Q2 operating expenses USD 193.82 million.
- Q2 net income USD -18.551 million
- Q2 product sales USD 173.912 million vs. IBES estimate USD 169.7 million
- Q2 basic EPS USD -0.43
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fitch "shows mercy" and maintains France's A+ rating, but warns that uncontrolled deficits could lead to a downgrade
Fitch Ratings recently announced that it is maintaining France's sovereign credit rating at "A+" with a "stable" outlook, even though the agency has once again warned that sustained fiscal deficits and rising public debt amidst increasing political uncertainty could still trigger a future rating downgrade.
Here’s Why XRP Price Just Crashed Sharply
What Can We Expect from Bitcoin (BTC) and Dogecoin (DOGE) Prices in the Coming Days?
BTC Recovers From Sub-$77K Dip, XRP Drops Below $1.40: Weekend Watch
Crypto prices
More
